Literature DB >> 26943153

PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21.

Ji-Young Lee1, Mihee Yun1, Ji-Sun Paik2, Seong-Beom Lee1, Suk-Woo Yang2.   

Abstract

PURPOSE: The aim of this study was to investigate the effect of platelet-derived growth factor (PDGF)-BB on the proliferation of cells and its possible mechanism in human orbital fibroblasts.
METHODS: Human orbital fibroblasts were obtained from orbital fat from decompression surgery in patients with thyroid-associated ophthalmopathy (TAO). The cells were treated with PDGF-BB, and the number of cells was counted using an Advanced Detection and Accurate Measurement (ADAM) automatic cell counter. The expression of programmed cell death 4 (PDCD4) was determined by Western blotting. The effect of PDCD4 on cell proliferation was evaluated using PDCD4 small interfering RNA (siRNA)-transfected cells. The level of microRNA-21 (miRNA-21) was measured by quantitative real-time RT-PCR. In addition, the role of miRNA-21 in the proliferation of PDGF-BB-treated cells was assessed by means of anti-miRNA-21 siRNA and resveratrol (trans-3,4',5-trihydroxys-tilbene), an inhibitor of miRNA-21.
RESULTS: PDGF-BB was found to enhance cell proliferation, whereas it inhibited PDCD4 expression in human orbital fibroblasts. Down-regulation of PDCD4 by PDCD4 siRNA transfection significantly increased the number of human orbital fibroblasts. In addition, PDGF-BB increased the level of miRNA-21 in human orbital fibroblasts. Transfection with anti-miRNA-21 and treatment with resveratrol partially restored the expression of PDCD4 and led to a reduction in cell number in PDGF-BB-treated orbital fibroblasts.
CONCLUSIONS: PDGF-BB enhances proliferation by suppressing PDCD4 expression by up-regulation of miRNA-21 in human orbital fibroblasts. These results suggest that PDGF-BB stimulates cell proliferation through microRNA-21-mediated PDCD4 down-regulation, leading to the development of TAO.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26943153     DOI: 10.1167/iovs.15-18157

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

Review 1.  Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson's Disease Pathogenesis and Treatment.

Authors:  Dan Li; Le-Tian Huang; Cheng-Pu Zhang; Qiang Li; Jia-He Wang
Journal:  Front Aging Neurosci       Date:  2022-07-01       Impact factor: 5.702

Review 2.  Mesenchymal Stem Cells from Adipose Tissue in Clinical Applications for Dermatological Indications and Skin Aging.

Authors:  Meenakshi Gaur; Marek Dobke; Victoria V Lunyak
Journal:  Int J Mol Sci       Date:  2017-01-20       Impact factor: 5.923

3.  A Novel Competing Endogenous RNA Network Associated With the Pathogenesis of Graves' Ophthalmopathy.

Authors:  Zifan Yue; Pei Mou; Sainan Chen; Fei Tong; Ruili Wei
Journal:  Front Genet       Date:  2021-12-15       Impact factor: 4.599

4.  miR-96-5p Induces Orbital Fibroblasts Differentiation by Targeting Smad7 and Promotes the Development of Thyroid-Associated Ophthalmopathy.

Authors:  Jianshu Kang; Yunqin Li; Yue Zou; Zhijian Zhao; Linan Jiao; Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-27       Impact factor: 2.629

Review 5.  Research progress on the pathogenesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes.

Authors:  Jingyi Zheng; Honghong Duan; Sufang You; Bo Liang; Yuping Chen; Huibin Huang
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

6.  A negative correlation of axial length with aqueous humor concentration of cytokines in patients with congenital cataracts.

Authors:  Fan Zhang; Pingjun Chang; Yinying Zhao; Yune Zhao
Journal:  Mol Vis       Date:  2020-03-03       Impact factor: 2.367

Review 7.  Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves' Ophthalmopathy.

Authors:  Yan Wang; Xiao-Min Ma; Xin Wang; Xin Sun; Ling-Jun Wang; Xin-Qi Li; Xiao-Yan Liu; Hong-Song Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.